MENLO PARK, Calif., April 12, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that two new analyses of phase 3 clinical data of Gralise™ (gabapentin), a once-daily evening formulation of gabapentin for management of postherpetic neuralgia (PHN), will be presented this week at the 63rd Annual Meeting of the American Academy of Neurology in Honolulu, Hawaii. A poster to be presented this evening concludes that there was no effect of previous treatment with gabapentin and pregabalin on the efficacy or adverse event (AE) profile of Gralise. An oral presentation to be given Thursday evening will review the overall tolerability and safety dataset from two phase 3 clinical trials of once-daily Gralise. Gralise was recently approved by the U.S. Food and Drug Administration and will be available in pharmacies in the fourth quarter of 2011.
